AMGNCL Stock Financial Analysis - Amgen Inc. (SNSE) Stock

Overview

Amgen Inc., based in the United States, is a prominent biotechnology firm deeply engaged in the development, manufacture, and marketing of therapeutic products for oncology, nephrology, bone health, cardiovascular disease, and inflammation. The company is renowned for its strategic focus on innovative biological treatments and continuous investment in biotechnological research and development to address complex diseases. Key projects include pioneering work in biosimilar products and targeted cancer therapies, which align with its mission to serve patients by transforming new scientific discoveries into advances in medical treatment. Amgen's strong portfolio of patents and collaborative efforts with other industry leaders underscore its influential role in the biotech sector.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Amgen Inc. as of June 30, 2025 is 34,917.00 MM.
The operating income for Amgen Inc. as of June 30, 2025 is 10,738.00 MM.
The net income for Amgen Inc. as of June 30, 2025 is 6,619.00 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	34,917.00	10,738.00	6,619.00
2025-03-31	34,126.00	10,265.00	5,933.00
2024-12-31	33,424.00	9,676.00	4,090.00
2024-09-30	32,534.00	9,874.00	4,230.00
2024-06-30	30,934.00	9,694.00	3,130.00
2024-03-31	29,532.00	9,341.00	3,763.00
2023-12-31	28,190.00	9,658.00	6,717.00
2023-09-30	26,833.00	8,599.00	7,566.00
2023-06-30	26,582.00	9,915.00	7,979.00
2023-03-31	26,190.00	9,583.00	7,917.00
2022-12-31	26,323.00	10,098.00	6,552.00
2022-09-30	26,330.00	10,221.00	6,835.00
2022-06-30	26,384.00	9,401.00	6,576.00
2022-03-31	26,316.00	9,638.00	5,723.00
2021-12-31	25,979.00	9,151.00	5,893.00
2021-09-30	25,767.00	9,018.00	5,609.00
2021-06-30	25,484.00	9,263.00	5,746.00
2021-03-31	25,164.00	9,163.00	7,085.00
2020-12-31	25,424.00	9,328.00	7,264.00
2020-09-30	24,987.00	9,388.00	7,352.00
2020-06-30

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31	11.04	10.94
2024-12-31	7.62	7.56
2024-09-30	7.89	7.85
2024-06-30	5.84	5.81
2024-03-31	7.03	7.01
2023-12-31	12.56	12.49
2023-09-30	14.14	14.06
2023-06-30	14.93	14.85
2023-03-31	14.81	14.72
2022-12-31	12.18	12.11
2022-09-30	12.54	12.49
2022-06-30	11.89	11.82
2022-03-31	10.17	10.12
2021-12-31	10.34	10.28
2021-09-30	9.77	9.70
2021-06-30	9.92	9.86
2021-03-31	12.16	12.07
2020-12-31	12.40	12.31
2020-09-30	12.48	12.40
2020-06-30	12.33	12.24

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Amgen Inc. as of June 30, 2025 is 12,013.00 MM.
The cash from investing activities for Amgen Inc. as of June 30, 2025 is -1,448.00 MM.
The cash from financing activities for Amgen Inc. as of June 30, 2025 is -11,838.00 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	12,013.00	-1,448.00	-11,838.00
2025-03-31	12,192.00	-1,276.00	-11,814.00
2024-12-31	11,490.00	-1,046.00	-9,415.00
2024-09-30	7,257.00	-27,733.00	-5,254.00
2024-06-30	6,446.00	-27,785.00	-3,608.00
2024-03-31	8,096.00	-27,779.00	-2,169.00
2023-12-31	8,471.00	-26,204.00	21,048.00
2023-09-30	10,582.00	-2,588.00	17,245.00
2023-06-30	10,800.00	-2,593.00	20,838.00
2023-03-31	8,621.00	-4,575.00	20,986.00
2022-12-31	9,721.00	-6,044.00	-4,037.00
2022-09-30	9,880.00	-2,801.00	-9,546.00
2022-06-30	9,320.00	-2,461.00	-8,286.00
2022-03-31	9,321.00	941.00	-9,846.00
2021-12-31	9,261.00	733.00	-8,271.00
2021-09-30	8,606.00	-421.00	-5,303.00
2021-06-30	9,556.00	-2,122.00	-9,949.00
2021-03-31	10,467.00	-5,490.00	-6,552.00
2020-12-31	10,497.00	-5,401.00	-4,867.00
2020-09-30	10,858.00	-9,980.00	-3,206.00
2020-06-30

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Management Effectiveness

The roa for Amgen Inc. as of June 30, 2025 is 0.07.
The roe for Amgen Inc. as of June 30, 2025 is 1.12.
The roic for Amgen Inc. as of June 30, 2025 is 0.09.
The croic for Amgen Inc. as of June 30, 2025 is -0.01.
The ocroic for Amgen Inc. as of June 30, 2025 is 0.19.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.07	1.12	0.09	-0.01	0.19
2025-03-31	0.04	0.81	0.06	0.02	0.17
2024-12-31	0.04	0.66	0.06	-0.38	0.11
2024-09-30	0.03	0.55	0.05	-0.36	0.09
2024-06-30	0.04	0.70	0.05	-0.31	0.12
2024-03-31	0.10	1.83	0.09	0.05	0.12
2023-12-31	0.12	2.07	0.11	0.37	0.16
2023-09-30	0.13	3.30	0.12	0.43	0.16
2023-06-30	0.13	3.30	0.12	0.42	0.16
2023-03-31	0.13	8.64	0.12	0.37	0.13
2022-12-31	0.11	0.83	0.16	-0.06	0.23
2022-09-30	0.11	0.83	0.16	-0.06	0.23
2022-06-30	0.11	0.80	0.17	-0.04	0.24
2022-03-31	0.09	0.61	0.15	0.01	0.24
2021-12-31	0.09	0.63	0.14	0.04	0.23
2021-09-30	0.09	0.51	0.12	0.06	0.19
2021-06-30	0.09	0.54	0.14	-0.06	0.23
2021-03-31	0.11	0.75	0.17	-0.04	0.25
2020-12-31	0.12	0.75	0.17	0.01	0.24
2020-09-30	0.12	0.67	0.16	-0.05	0.24
2020-06-30	0.12	0.68	0.16	0.08	0.24

Gross Margins

The gross margin for Amgen Inc. as of June 30, 2025 is 0.70.
The net margin for Amgen Inc. as of June 30, 2025 is 0.17.
The operating margin for Amgen Inc. as of June 30, 2025 is 0.31.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.70	0.17	0.31
2025-03-31	0.69	0.12	0.30
2024-12-31	0.71	0.13	0.29
2024-09-30	0.71	0.10	0.28
2024-06-30	0.66	0.13	0.24
2024-03-31	0.84	0.24	0.48
2023-12-31	0.67	0.28	0.31
2023-09-30	0.75	0.30	0.39
2023-06-30	0.75	0.30	0.39
2023-03-31	0.75	0.30	0.37
2022-12-31	0.76	0.26	0.37
2022-09-30	0.76	0.26	0.37
2022-06-30	0.76	0.25	0.36
2022-03-31	0.75	0.22	0.37
2021-12-31	0.75	0.23	0.36
2021-09-30	0.75	0.22	0.35
2021-06-30	0.75	0.23	0.36
2021-03-31	0.76	0.28	0.36
2020-12-31	0.76	0.29	0.37
2020-09-30	0.77	0.29	0.38
2020-06-30	0.78	0.30	0.38

PE:AMGN
MX:AMGN
IT:1AMGN	€239.60
GB:0R0T
DE:AMG	€241.35
AT:AMGN
GB:AMGD
CH:000907582
CL:AMGN
US:AMGN	$283.64